IP Library Granted Patent US 10,881,582
Granted Patent B2
US 10,881,582 · App. 16/004,858 · Granted Jan 5, 2021

Individual dose pack

Inventors: Sriman Banerjee (Warren, NJ); Kathryn Cramer (Mazomanie, WI); Gautam Debnath (West Bengal, IN)
Assignee: GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
A61J1/1431A47J31/407A61J1/1443B65D85/8046B65D2215/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,881,582
App. No.
16/004,858
Granted
Jan 5, 2021
Kind
B2
Abstract

Aspects of the present invention are directed to an individual dose pack. The individual dose pack may comprise a single serving pod and an overwrap surrounding the entirety of the single serving pod and sealing the single serving pod therein, wherein the overwrap is child-resistant and creates an impermeable barrier being resistant to the passage of liquids and gases. The single serving pod may include a cup, at least one pharmaceutical active ingredient provided in the cup, and a lid affixed to the cup. The overwrap is a multi-layer structure including a first layer being a biaxially-oriented polyethylene terephthalate layer, a second layer being a polyethylene layer, a third layer being an aluminum foil layer, and fourth layer being an ionomer layer.

Claims (39)

1. An individual dose pack for use with an automatic brewing machine comprising:

a single serving pod including:

a cup having a bottom portion and a side wall portion extending from the bottom portion to a rim surrounding an opening, the space between the bottom portion and the side wall portion defining an interior space,

at least one pharmaceutical active ingredient provided in the interior space of the cup, and

a lid affixed to the rim of the cup thereby closing the opening and securing the at least one pharmaceutical active ingredient within the interior space of the cup; and

an overwrap surrounding the entirety of the single serving pod and sealing the single serving pod therein, wherein the overwrap creates an impermeable barrier being resistant to the passage of liquids and gases,

wherein the overwrap is a multi-layer structure including a first layer being a biaxially-oriented polyethylene terephthalate layer, a second layer being a polyethylene layer, a third layer being an aluminium foil layer, and a fourth layer being an ionomer layer,

wherein the overwrap is 100% child-resistant with zero openings registered as determined by a Child-Resistant Test, and

wherein the Child-Resistant Test was performed in accordance with The Poison Prevention Packaging Act of 1970 Regulations and The Code of Federal Regulations Title 16: Part 1700.20.

2. The individual dose pack according to claim 1 , wherein the at least one pharmaceutical active ingredient is acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, ibuprofen, pseudoephedrine, guaifenesin, acetylcysteine, chlorpheniramine, cetirizine, levocetirizine, doxylamine succinate, loratadine, doxylamine, or a combination thereof.

3. The individual dose pack according to claim 2 , wherein the at least one pharmaceutical active ingredient is acetaminophen.

4. The individual dose pack according to claim 2 , wherein the at least one pharmaceutical active ingredient is a combination of acetaminophen, phenylephrine, and dextromethorphan.

5. The individual dose pack according to claim 2 , wherein the at least one pharmaceutical active ingredient is a combination of acetaminophen, phenylephrine, and diphenhydramine.

6. The individual dose pack according to claim 2 , wherein the at least one pharmaceutical active ingredient is a combination of guaifenesin and dextromethorphan.

7. The individual does pack according to claim 1 , wherein the overwrap has a thickness between about 70-100 microns.

8. The individual does pack according to claim 1 , wherein the first layer of the overwrap has a thickness between about 20-30 microns.

9. The individual does pack according to claim 1 , wherein the second layer of the overwrap has a thickness between about 10-20 microns.

10. The individual dose pack according to claim 1 , wherein the third layer of the overwrap has a thickness between about 7-12 microns.

11. The individual does pack according to claim 1 , wherein the fourth layer of the overwrap has a thickness between about 30-40 microns.

12. The individual does pack according to claim 1 , wherein the overwrap has a moisture vapor transmission rate of less than 0.001 g H 2 O/100 in 2 /24 hours.

13. The individual dose pack according to claim 1 , wherein the overwrap has an oxygen transmission rate of less than 0.001 cc/100 in 2 /24 hours.

14. The individual dose pack according to claim 1 , wherein the overwrap has a length between about 130-140 mm and a width between about 80-90 mm when laid flat.

15. The individual dose pack according to claim 1 , wherein the fourth layer of one end of the overwrap is folded and adhered to the fourth layer of another end of the overwrap to create a sealed portion and seal the single serving pod within the overwrap.

16. A multi-layer overwrap comprising:

a first layer being a biaxially-oriented polyethylene terephthalate layer;

a second layer being a polyethylene layer;

a third layer being an aluminium foil layer;

and a fourth layer being an ionomer layer,

wherein the overwrap creates an impermeable barrier being resistant to the passage of liquids and gases,

wherein the overwrap is 100% child-resistant with zero openings registered as determined by a Child-Resistant Test, and

wherein the Child-Resistant Test was performed in accordance with The Poison Prevention Packaging Act of 1970 Regulations and The Code of Federal Regulations Title 16: Part 1700.20.

17. The multi-layer overwrap according to claim 16 , wherein the multi-layer overwrap is 100% senior adult accessible with zero unsuccessful attempts to open registered as determined by a Senior Adult Test, and wherein the Senior Adult Test was performed in accordance with The Poison Prevention Packaging Act of 1970 Regulations and The Code of Federal Regulations Title 16: Part 1700.20.

18. The multi-layer overwrap according to claim 16 , wherein the first layer of the multi-layer overwrap has a thickness between about 20-30 microns.

19. The multi-layer overwrap according to claim 16 , wherein the second layer of the multi-layer overwrap has a thickness between about 10-20 microns.

20. The multi-layer overwrap according to claim 16 , wherein the third layer of the multi-layer overwrap has a thickness between about 7-12 microns.

21. The multi-layer overwrap according to claim 16 , wherein the fourth layer of the multi-layer overwrap has a thickness between about 30-40 microns.

22. The multi-layer overwrap according to claim 16 , wherein the multi-layer overwrap has a moisture vapor transmission rate of less than 0.001 g H 2 O/100 in 2 /24 hours.

23. The multi-layer overwrap according to claim 16 , wherein the multi-layer overwrap has an oxygen transmission rate of less than 0.001 cc/100 in 2 /24 hours.

24. The individual dose pack according to claim 1 , wherein the individual dose pack is 100% senior adult accessible with zero unsuccessful attempts to open registered as determined by a Senior Adult Test, and wherein the Senior Adult Test was performed in accordance with The Poison Prevention Packaging Act of 1970 Regulations and The Code of Federal Regulations Title 16: Part 1700.20.

Assignments (3)
CHANGE OF NAME Recorded Mar 1, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066713/0558 →
CHANGE OF NAME Recorded Feb 28, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066701/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2018
From: BANERJEE, SRIMAN; CRAMER, KATHRYN; DEBNATH, GAUTAM
To: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
Reel/Frame 047334/0605 →
Continuity (1)
Related Publication 20190374433A1 · Dec 12, 2019